Table 3.
Subgroup analyses for validation of performance of RMI, CA125, GOT-1 (RMI + HE4), and GOT-2 (CA125 + HE4) comparing benign disease with EOC in early-and late stage tumors.
| Group (n) | Model | FIGO I + II | FIGO III + IV | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ROC | SN% (75% SP) | SP% (Target SN) | ROC | SN% (75% SP) | SP% (Target SN) | ||||
| AUC | 95% CI | AUC | 95% CI | ||||||
| Benign (445) vs. EOC FIGO I + II (52)/FIGO III + IV (83) |
RMI (cut-off < 200) | 0.90 | 0.85–0.94 | 94 | 84 | 0.98 | 0.97-0.99 | 99 | 84 |
| GOT-1 (RMI + HE4) | 0.90 | 0.86–0.95 | 92 | 86 | 0.98 | 0.97-1.00 | 99 | 90 | |
| Benign (445) vs. EOC FIGO I + II (52)/FIGO III + IV (83) |
CA125 (cut-off > 35 U/mL) | 0.84 | 0.79–0.90 | 75 | 68 | 0.96 | 0.94-0.98 | 96 | 68 |
| GOT-2 (CA125 + HE4) | 0.88 | 0.82–0.93 | 85 | 74 | 0.98 | 0.96-1.00 | 99 | 81 | |
Specificity was calculated using target SN. Target SN = target sensitivity of RMI at cut-off >200 was 83% (early stage) and 98% (late stage); target sensitivity of CA125 at cut-off >35 was 85% (early stage) and 98% (late stage). AUC = area under the curve; EOC = epithelial ovarian cancer; FIGO = International Federation of Gynecology and Obstetrics; FIGO I+II = Early stage tumors; FIGO III+IV = EOC late stage tumors; GOT-1 = Gothenburg index 1; GOT-2 = Gothenburg index 2; Pre-M = premenopausal; Post-M = postmenopausal; RMI = risk of malignancy index; ROC = receiver operating characteristics; SN = sensitivity; SP = specificity.